Overview

An Open-Label Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of OV101 in Individuals With Angelman Syndrome

Status:
Unknown status

Trial end date:
2020-09-01

Target enrollment:

Participant gender:

Summary

This open-label study (OV101-18-002) will evaluate the long-term (52 weeks) safety of OV101 in subjects with AS and provide additional OV101 treatment to those subjects who completed Study OV101-15-001 (NCT02996305). Subjects with AS who completed the pharmacokinetic Study OV101-16-001 (NCT03109756) will also be permitted to participate, provided they meet all entry criteria.

Phase:

Phase 2

Details

Lead Sponsor:

Ovid Therapeutics Inc.

Treatments:

Gaboxadol